Mango Sciences

Name: Mango Sciences
Brand: Mango Sciences

Accelerating Global Precision Medicine for the Benefit of All

LinkedIn 9K|Website|FTEs 37|HQ Boston, Massachusetts, US

01Competitive Landscape

Narrative analysis

- Mango versus TriNetX: TriNetX is well established for feasibility and cohort discovery across large health system networks. Mango’s distinguishing claim in public materials is a focus on emerging-market and underrepresented oncology populations and associated affordability programs, subject to validation. - Mango versus IQVIA: IQVIA provides broad RWE capabilities and global services at significant scale. Mango may be relevant where buyers seek a specialized partner focused on emerging markets and oncology-affordability challenges. - Mango versus Flatiron/ConcertAI/Tempus: These vendors have substantial oncology-focused assets and often strong US footprints. Mango’s emerging-market data focus could be relevant when research requires those specific populations and when data provenance and methodology meet buyer standards.

When customers choose competitors instead (likely reasons)

Common selection drivers across the category include:

Need for publicly documented compliance and trust-center artifacts (SOC 2, HITRUST, ISO)
Need for a large volume of reference customers and published validation
Need for proven regulatory-grade evidence workflows and established methodological documentation

	Mango Sciences (Querent™)	TriNetX	IQVIA Real World Evidence
Starting Price	Not public (enterprise contracts)	Not public (enterprise / negotiated)	Not public (enterprise / services + data licensing)
Most appropriate for	Emerging-market oncology access, trial intelligence, and affordability-focused programs	Cohort discovery, feasibility, global RWE network access	End-to-end global RWE and CRO-scale execution, broad data assets and services
Key Strength	Focus on non-Caucasian / emerging-market oncology data and patient affordability/access programs (vendor/partner claims)	Large network approach and institutional adoption; mature feasibility and cohorting workflows	Scale, breadth, and integration with CRO/services; deep enterprise presence
Key Weakness	Limited public third-party validation, limited public security documentation, scarce public product reviews	Cost and contracting complexity common to large RWE vendors	Potentially expensive, heavyweight engagements and vendor lock-in risk

01Competitive Landscape

Narrative analysis

Mango versus TriNetX: TriNetX is well established for feasibility and cohort discovery across large health system networks. Mango’s distinguishing claim in public materials is a focus on emerging-market and underrepresented oncology populations and associated affordability programs, subject to validation.
Mango versus IQVIA: IQVIA provides broad RWE capabilities and global services at significant scale. Mango may be relevant where buyers seek a specialized partner focused on emerging markets and oncology-affordability challenges.
Mango versus Flatiron/ConcertAI/Tempus: These vendors have substantial oncology-focused assets and often strong US footprints. Mango’s emerging-market data focus could be relevant when research requires those specific populations and when data provenance and methodology meet buyer standards.

When customers choose competitors instead (likely reasons)

Common selection drivers across the category include:

Need for publicly documented compliance and trust-center artifacts (SOC 2, HITRUST, ISO)
Need for a large volume of reference customers and published validation
Need for proven regulatory-grade evidence workflows and established methodological documentation

	Mango Sciences (Querent™)	TriNetX	IQVIA Real World Evidence
Starting Price	Not public (enterprise contracts)	Not public (enterprise / negotiated)	Not public (enterprise / services + data licensing)
Most appropriate for	Emerging-market oncology access, trial intelligence, and affordability-focused programs	Cohort discovery, feasibility, global RWE network access	End-to-end global RWE and CRO-scale execution, broad data assets and services
Key Strength	Focus on non-Caucasian / emerging-market oncology data and patient affordability/access programs (vendor/partner claims)	Large network approach and institutional adoption; mature feasibility and cohorting workflows	Scale, breadth, and integration with CRO/services; deep enterprise presence
Key Weakness	Limited public third-party validation, limited public security documentation, scarce public product reviews	Cost and contracting complexity common to large RWE vendors	Potentially expensive, heavyweight engagements and vendor lock-in risk

Mango Sciences

01Competitive Landscape

Narrative analysis

When customers choose competitors instead (likely reasons)

02Market Map

01Competitive Landscape

Narrative analysis

When customers choose competitors instead (likely reasons)

02Market Map